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The  use  of  embryonic  stem  cells  (ESCs)  and their  progeny  in  high  throughput  drug  discovery  and  regen-
erative  medicine  will  require  production  at  scale  of  well  characterized  cells  at  an  appropriate  level  of
purity.  The  adoption  of automated  bioprocessing  techniques  offers the  possibility  to  overcome  the  lack
of  consistency  and  high  failure  rates  seen  with  current  manual  protocols.  To  build  the case  for  increased
use  of  automation  this  work  addresses  the key  question:  “can  an automated  system  match  the  quality  of  a
highly skilled  and  experienced  person  working  manually?”  To answer  this  we ﬁrst describe  an  integrated
automation  platform  designed  for the ‘hands-free’  culture  and  differentiation  of  ESCs  in  microwell  for-
mats.  Next  we  outline  a framework  for the  systematic  investigation  and optimization  of key  bioprocess
variables  for  the  rapid  establishment  of  validatable  Standard  Operating  Procedures  (SOPs).  Finally  the
experimental  comparison  between  manual  and  automated  bioprocessing  is  exempliﬁed  by  expansion  of
the murine  Oct-4-GiP  ESC  line  over  eight  sequential  passages  with  their  subsequent  directed  differenti-
ation  into  neural  precursors.  Our  results  show  that  ESCs  can be effectively  maintained  and  differentiated
in  a highly  reproducible  manner  by the automated  system  described.  Statistical  analysis  of the  results  for
cell growth  over  single  and  multiple  passages  shows  up  to a  3-fold  improvement  in  the consistency  of cell
growth  kinetics  with  automated  passaging.  The  quality  of the cells  produced  was evaluated  using a  panel
of  biological  markers  including  cell  growth  rate  and viability,  nutrient  and  metabolite  proﬁles,  changes
in  gene  expression  and  immunocytochemistry.  Automated  processing  of the  ESCs  had  no  measurable
negative  effect  on  either  their  pluripotency  or their  ability  to differentiate  into  the  three  embryonic  germ
layers.  Equally  important  is  that  over  a  6-month  period  of  culture  without  antibiotics  in the  medium,
we  have  not  had any  cases  of culture  contamination.  This  study  thus  conﬁrms  the  beneﬁts  of  adopting
utes  tautomated  bioprocess  ro
. Introduction
Embryonic stem cells (ESCs) are currently being evaluated for
otential application in a number of diverse areas including regen-
rative medicine [1], drug discovery and development [2–4] or
s routes for delivery of gene therapies [5]. The high level of
nterest is a consequence of the ability of ESCs to self renew indef-
nitely and to differentiate into almost every somatic cell type
6–10].
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Effective exploitation of ESCs is, however, predicated upon
the ability to reproducibly derive, manipulate and efﬁciently
differentiate these cells on a suitable scale at an appropriate level
of purity [11–15]. The often reported lack of reproducibility in ESC
processing is a consequence of the large number of processing steps
involved, generally carried out using largely uncontrolled and man-
ual operations. Previous work in our laboratory and elsewhere has
shown that ESCs are particularly sensitive to the microenvironment
prevalent during processing [11,16–18]. For example, the effect
of physical forces on cells due to ﬂuid ﬂow during pipetting was
shown to be highly signiﬁcant resulting in a large degree of culture
variability among similarly trained operators. Automation of ESC
handling offers the potential to reduce such variation since applied
physical forces may  be tightly controlled and applied consistently
throughout a culture, and from culture to culture [19].
A number of initial publications on the automation of aspects of
ESC processing have appeared in the last few years. The ﬁrst was
that of Joannides and co-workers [20] who modiﬁed an existing
 reserved.
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Fig. 1. Automation platform for the reproducible culture and differentiation of mouse embryonic stem cells. (a) Photograph of liquid handling robot contained within the
Class-2 design biosafety cabinet. (b) Schematic layout of the robotic deck showing access (dashed lines) to the integrated CO2 incubator (plate conveyor belt) and microplate
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dentrifuge (via the Tecan RoMa arm).
tissue chopping device’ to create an instrument for the automated
echanical passaging of human ESCs. This work was the ﬁrst to
ddress the pressing need for standardization of routine, and often
ariable laboratory work with a view to processing stem cells at
cale for therapy. The use of automated liquid handling to address
he issue of standardization of physical forces resultant of ﬂuid ﬂow
as also been reported [19]. In this case the plating out of both
uman and murine ESCs using a liquid handling robot was  reported
long with automated media exchanges. Complete automated pas-
aging of ESCs was precluded by the lack of an integrated centrifuge
o facilitate removal of cell dissociating agents. Automated expan-
ion of ESCs in traditional T-ﬂasks has also been reported [21]. It
as shown that ESCs can be routinely maintained and expanded
n an automated T-ﬂask system yielding cell numbers at the scale
equired for therapeutic applications. Most recently, murine ESCs
ave been expanded in microplates on an automated liquid hand-
ing platform and further differentiated into cardiomyocytes by
mbryoid body (EB) differentiation on a separate microﬂuidic liquid
andling workstation [22], which is optimal for high-throughput
creening. Manual transfer of cells was required however between
he expansion and differentiation stage. Furthermore, none of the
latforms described incorporation of the key centrifugation step to
acilitate enzymatic passaging of cells. To date then, there remains
o report in the literature on the complete, hands-free automation
f all key steps in the processing of ESCs including trypsinization,
entrifugation and cell differentiation.
In this work, we address a key question related to the use of
tem cells in drug discovery and future development of the regen-
rative medicine industry [12]: ‘Can an automated system match
he quality of a highly skilled and experienced person working
anually?’ Consequently, we describe an integrated automation
latform (Fig. 1(a)) for the ‘hands-free’ expansion and differenti-
tion of ESCs. Related to this is a framework for the systematic
nvestigation and optimization of key bioprocess variables in order
o deﬁne validatable Standard Operating Procedures (SOPs) for
utomation platform operation. The comparison between auto-
ated and manual processing is exempliﬁed by the maintenance
f the murine ESC line Oct-4-GiP [23], in 24-well microtitre plates,
ver eight sequential passages. The subsequent automated and
irected neural differentiation of these ESCs is also demonstrated.
ur results show that ESCs can be effectively maintained and differ-
ntiated in a highly reproducible manner by the automated system
escribed.2. Materials and methods
2.1. Routine cell culture and maintenance
The mouse embryonic stem cell line Oct-4-GiP [23] was used
throughout this work and was  kindly provided by Stem Cell Sci-
ences (Cambridge, UK). The cells were cultured under feeder-free
conditions on Iwaki tissue culture treated plastic (SLS, Notting-
ham, UK) coated with 0.1% (w/v) gelatine (Sigma, Poole, UK).
Routine maintenance of the cells was carried out in T-ﬂasks and all
other experimental work was carried out in 24-well microplates.
For undifferentiated cell growth the culture medium consisted
of Glasgow Minimum Essential Medium (GMEM) supplemented
with 0.1 mM -mercaptoethanol, MEM  nonessential amino acids,
1 mM sodium pyruvate, 2 mM l-glutamine (all Invitrogen, Pais-
ley, UK), 10% (v/v) foetal bovine serum (SLS, Nottingham, UK)
and 1 × 103 U mL−1 leukemia inhibitory factor, LIF (Chemicon, UK).
All stated concentrations are ﬁnal. Cell dissociation was routinely
achieved by removal of the culture medium followed by washing
with Dulbecco’s PBS (DPBS, Sigma, Poole, UK) and subsequent incu-
bation for 4 min  at 37 ◦C in the presence of 0.025% (w/v) trypsin
supplemented with 0.372 g L−1 EDTA and 1% (v/v) chicken serum
(all Sigma, Poole, UK). Following incubation the trypsinized cells
were quenched using fresh culture medium and centrifuged for
3 min  at 280 × g in an Eppendorf 5810R centrifuge in the case of
manual cultures or in a Hettich Rotanta 46 RSC centrifuge in the
case of automated culture. Following centrifugation and super-
natant removal, the cells were resuspended in growth medium and
replated onto a fresh gelatinized microtitre plate at the desired
Inoculation Cell Density (ICD). Cultures were maintained in a
humidiﬁed incubator at 37 ◦C with 5% (v/v) CO2.
2.2. Directed monolayer neuronal differentiation
ESCs were cultured manually for 2 days in serum containing
medium in the presence of LIF as described in Section 2.1. Seeding
at 3 × 104 cells cm−2 in a T-25 ﬂask typically yields around 6 × 106
cells after 48 h. Differentiation was  performed in Iwaki 6-well
plates, the wells previously being gelatinized for around 1 h with
0.1% (w/v) gelatine at room temperature and then the excess
gelatine removed. The cells were harvested by incubation with
0.025% (w/v) trypsin (containing 1% (v/v) chick serum) for ∼4 min
as described in Section 2.1 and quenched with serum containing
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Fig. 2. Detail of Standard Operating Procedures (SOPs) devised for the ‘hands free’ automated expansion and differentiation of mESCs; (a) single stage passage of adherent
c icated
i e robo
m
3
)
T
r
d
f
t
aell  culture and (b) replating of cells for monolayer differentiation (dashed lines ind
nc:  CO2 incubator, G: Genesis tilting platform (positions numbered from back of th
edium without LIF. The cells were centrifuged at 280 × g for
 min, the supernatant removed and the pellet resuspended in LIF(-
 medium. The cells were counted by Guava ExpressPlusTM (Guava
echnologies, Lincolnshire, UK) ﬂow cytometry and appropriately
esuspended in LIF(-) medium containing serum to achieve a cell
ensity of 5 × 103 cells cm−2 and seeded in the plate overnight. The
ollowing morning all the serum containing medium was  removed,
he wells were washed with PBS (without calcium or magnesium),
nd NDIFF–RHBA medium (Stem Cell Sciences, Cambridge, UK) manual cell count). Nomenclature: o: RoMa gripper open, g: Roma gripper closed,
t deck forwards), DiTi: disposable tip, and Z: vertical height of the pipetting arm.
added. Medium was subsequently exchanged every 2 days, until
the emergence of neuronal morphology (particularly axons) which
was typically after 8–10 days. Cultures were maintained in a
humidiﬁed incubator at 37 ◦C with 5% (v/v) CO2.2.3. Embryoid body differentiation
ESCs propagated in T-ﬂasks, following thawing of an Oct-4-GiP
vial, were harvested as described in Section 2.1 and resuspended
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n serum containing medium in the absence of LIF. Approximately
ne tenth of the cells were reseeded into a 10 cm bacteriological
etri dish (Sterilin, Caerphilly, UK) and further medium containing
erum, without LIF was  added. Medium was exchanged every 3–4
ays. EBs were harvested after ∼8 days, washed with PBS (without
alcium and magnesium) and stored at −80 ◦C for RNA extrac-
ion. Further EB differentiation experiments were performed on
ells after undergoing 8 passages, either automated or manual, in
4-well plates.
.4. Automation platform description
The automated pipetting station used in this study was  a Tecan
reedom Evo 100 (Tecan, Reading, UK) equipped with one four-
hannel liquid handling arm and one gripper, RoMa, arm. This was
oused in a Class 2 design biological safety cabinet (Walker Safety
abinets, Derbyshire, UK), capable of environmental control (tem-
erature, O2 and CO2 levels), and its operation integrated with a
icroplate centrifuge (Hettich Rotanta 46 RSC, Bach, Switzerland)
nd an automated CO2 incubator (Cytomat C450S, Basingstoke, UK)
s shown in Fig. 1(a). The liquid handling arm was  equipped with
 mL  syringes and was used with disposable tips only to minimize
ross contamination. Control of the automated platform and the
ssociated peripherals was through EvowareTM Standard (v2.4). A
chematic of the automated platform deck indicating the location
f on-deck devices, such as a microplate tilting rack and shaker, is
hown in Fig. 1(b).
.5. Automated Standard Operating Procedures (SOPs)
The SOP devised for automated, hands-free ESC expansion is
hown in Fig. 2(a). Before commencing each automated passage, all
eagents were replenished and pre-warmed in the reagent trough
ack by circulating warm water through the jacket. Source plate and
estination plate locations were also inputted into the EvoWareTM
oftware depending on the type of experiment being performed.
ach culture plate was passaged after 2 days of growth which
e have previously shown was sufﬁcient to achieve >80% con-
uence and was optimal for maintaining the pluripotency of the
SCs [17]. Each plate was automatically removed from the incu-
ator and was positioned by the RoMa arm in a predeﬁned space
n the plate rack and the lid removed. The rack was  then tilted to
0◦ relative to the robotic deck and all media removed by aspi-
ation. Pre-warmed DPBS was next added and the surface of the
ell washed by moving the rack between 0◦ and 30◦ and back
ve times. The DPBS was then removed, and warm trypsin added
o each well. After ensuring the trypsin covered the surface, the
late was returned to the incubator for 5 min  at 37 ◦C. Once the
ncubation was complete the trypsin was quenched using serum
ontaining medium and the cell suspension mixed, by repeated
spiration and dispensing, to ensure efﬁcient recovery of cells.
he cell suspensions were then transferred to a 96-deep square
ell plate (ABgene, Epsom, UK) with conical bases for centrifuga-
ion. After centrifugation the supernatant was removed and the
ell pellet resuspended in fresh medium. In the case of ‘ﬁxed split’
ultures the cell suspensions were used to directly inoculate new
ultures using a deﬁned proportion of the cells; one sixth. For mea-
ured ICD cultures, the cell number was ﬁrst determined manually
sing the Guava ExpressPlusTM assay described in Section 2.6.1,
nd the volume of cell suspension to be transferred entered into
he EvoWareTM software.
Experiments to systematically optimize the automated pas-
aging of cells via trypsinization examined a number of critical
ariables including trypsin incubation time, number of pipette mix-
ng steps and aspiration/dispensing ﬂow rates. Optimum trypsin
ncubation time was determined by exposing conﬂuent 24-wellring Journal 77 (2013) 246– 257 249
microplate cultures to trypsin for various times after which
quenching medium was  added and the dissociated cell suspension
removed. A proportion of the cell suspension was  used to deter-
mine dissociated cell number using the Guava ExpressPlusTM assay
described in Section 2.6.1. The remainder of the cell suspension
was diluted by a factor of 5–10 depending on the cell number and
replated in a 24-well plate. Aggregate size distribution was then
determined by microscope inspection of 15 ﬁelds in 4 wells, per
condition. The cells that remained attached were further treated
with trypsin for 8 min  to ensure all the cells were removed and the
total cell number determined to allow for calculation of the dis-
sociation efﬁciency. This is deﬁned as the ratio of the number of
viable cells detached in the ﬁrst trypsinization to the total num-
ber of viable cells detached after the ﬁrst and second trypsinization
steps. Cell number and viability are presented as an average across
one plate. Initial experiments showed that the well-to-well varia-
tion was minimal and was  not affected by well location or sequence
of passaging.
The SOP devised for automated monolayer ESC differentiation
is shown in Fig. 2(b). Cells produced by microwell passaging were
washed, dissociated and centrifuged as for a standard passage with
the subsequent resuspension of the cells being carried out in serum
containing medium without LIF. Cell number was then determined
using the Guava ExpressPlusTM assay described in Section 2.6.1. A 6-
well Iwaki microtitre plate pre-coated with 0.1% (w/v) gelatine was
then inoculated with resuspended cells to an ICD of 5000 cells cm−2.
Standard GMEM based medium containing serum but without
LIF was  added to give a ﬁnal well volume of 2 mL  medium. The
plates were inoculated overnight and subsequently serum contain-
ing medium was removed and replaced with NDIFF–RHBA medium.
Throughout the course of the differentiation, a complete medium
exchange was automatically carried out every 48 h.
2.6. Analytical methods
2.6.1. Cell density, viability and GFP expression
Viable cell concentration and cell viability were measured by
staining 197 L of cell suspension (diluted to achieve a cell concen-
tration of 50–500 cells L−1) with 3 L of ViaCountTM stain (Guava
Technologies, Hayward, CA, USA). After 10 min  incubation the sam-
ples were analyzed on a Guava EasyCyte 96-well ﬂow cytometer
using Guava’s ExpressPlusTM software. The viable population was
gated based on co-staining with the ViaCount. GFP  expression was
determined using the PM3  channel of the Guava EasyCyte. A neg-
ative control for GFP expression was set up using the parental
E14TG2a cell line [23].
2.6.2. Quantitative RT-PCR
RNA was  ﬁrst extracted from cell pellets using the RNeasy Micro
Kit (Qiagen, Sussex, UK) according to the manufacturer’s instruc-
tions. The RNA was eluted in 12 L of RNase-free water and the
concentration was measured using a Nanodrop spectrophotome-
ter (Thermo Scientiﬁc, Delaware, USA), measuring absorbance at
wavelengths of 260 nm and 280 nm.  Subsequently 1 g of RNA
was used to synthesize ﬁrst strand cDNA using the RETROscript
First Strand Synthesis Kit (Applied Biosystems, Cheshire, UK), again
as per the manufacturer’s instructions, using random decamers
to prime the ﬁrst strand reaction. To conﬁrm successful reverse
transcription, a standard RT-PCR reaction was carried out for the
housekeeping gene ˇ-actin. Reactions were carried out using the
BIOTAQ PCR kit (Bioline Laboratories, London, UK) and the ˇ-actin
primers F-(seq) in a Veriti Thermal Cycler (Applied Biosystems,
Cheshire, UK). PCR products were run in 2.5% agarose gel to con-
ﬁrm the presence of the desired 77 bp band corresponding to the
correct -actin amplicon.
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sig. 3. Optimization of cell detachment kinetics from a 24-well microplate. (a) The
he  size of the aggregates removed. (b) The impact of the number of pipette aspirat
o  trypsin at 37 ◦C: () cell detachment yield, (•) viability, and () aggregate size. Ex
For gene expression analysis 1 L of the cDNA was  used in
 SYBR Green real time PCR reaction using the QuantiTect SYBR
reen PCR Kit and the pre-validated primers QuantiTect Primer
ssays (Qiagen, Sussex, UK) under the manufacturer’s proto-
ols, in a Mastercycler EP Realplex (Eppendorf, Stevenage, UK)
hermocycler. Primer sequences are proprietary but details can
e found at: https://www1.qiagen.com/GeneGlobe/Default.aspx.
rimer assays were as follows: Nanog (QT01076334), Oct3/4
Pou5F1)(QT00109186), Rex1 (Zfp42) (QT00299936), and ˇ-actin
QT01136772). For relative quantiﬁcation, the Ct method [24]
as used. RNA levels were normalized against the housekeeping
ene ˇ-actin and cDNA from passage 1 cells was used as the cali-
rator. All calculations were performed using the realplex software
Eppendorf, Stevenage, UK).
.6.3. Immunocytochemistry
Differentiated mESCs maintained on gelatine coated tissue cul-
ure plastic were ﬁxed using 4% (w/v) paraformaldehyde. After
ermeabilization and blocking, the cells were incubated for 1 h
t room temperature with primary antibodies directed against
rachyury, III-tubulin or alpha-fetoprotein (the primary antibody
as raised in mouse). Secondary antibodies (anti-mouse) conju-
ated with Cy-3 were used to visualize the antibodies, and the
ells were counter stained with DAPI. Negative controls were used
here the primary antibody was omitted. The stained cultures
ere viewed using an inverted ﬂuorescent microscope (Eclipse
E2000-U, Nikon, Surrey, UK). All antibodies were obtained from
bcam (Cambridge, UK).
. Results and discussion
.1. Framework for deﬁnition of Standard Operating Procedures
The next phase in the development of regenerative medicine
ioprocessing will see the application of rigorous experimen-
al design techniques [4] for the systematic analysis of factors
nﬂuencing the quantity and quality of cells produced by a par-
icular bioprocess [3,17,25]. The optimized factors and their levels
ill then need to be embedded within predeﬁned SOPs that are
menable to automation such that they can be carried out repro-
ucibly across multiple batches of cells. The SOPs must be devised
uch that, together with the chosen bioprocessing platform, theyct of trypsinization time on the detachment efﬁciency and viability of mESCs and
max = 0.3 ms−1) on the aggregate size and viability of the cells after 5 min  exposure
ents performed as described in Section 2.5.
meet current regulatory guidelines [26] for ensuring the consistent
production of cellular therapies that are safe for clinical application.
The initial selection of factors for investigation can be identi-
ﬁed by a combination of statistical Design of Experiments (DoE)
techniques [27] and an understanding of both stem cell biology
[14,28] and biochemical engineering fundamentals that impact
on the microenvironment to which cells are exposed [18,29–32].
For manufacturing purposes, and improved operational efﬁciency,
these investigations are best embedded within a Quality by Design
(QbD) approach [33]. In this work we  began by systematically inves-
tigating over 10 factors that inﬂuence automated ESC growth and
differentiation in microwell formats using a combination of DoE
and traditional experimental approaches. The factors investigated
included: culture ICD and duration, temperature, media pH, aspi-
ration and dispensing ﬂow rates, applied shear rate, trypsinization
time, cell disaggregation conditions, relative centrifugal force, cen-
trifugation time, and cell pellet resuspension rate. Initial factorial
experiments showed that the use of default automation settings
for trypsinization of cells led to a low yield of poor quality cells.
This proved to be a key bioprocess step and so this is discussed fur-
ther in Section 3.2. Centrifugation settings with centrifugal forces
of 300 × g, 600 × g, and 1000 × g were evaluated in earlier work by
Veraitch et al. [17]. Results showed that higher centrifugal forces
had a negative effect on viable cell concentration, therefore a cen-
trifugal force of 300 × g was used in this work. As noted by Kirouac
and Zandstra [15] it will also be necessary to incorporate methods
for assessing cell properties and their control within a particular
SOP but these are beyond the scope of the current work.
3.2. Trypsinization optimization
The model cell line employed in this work is transfected with
the Oct-4-GFPirespac transgene and expresses GFP under the con-
trol of the Oct-4 promoter [34]. It has been shown that Oct-4 is a key
factor in the maintenance of pluripotency and cell fate [35–37]. GFP
expression was  therefore taken as an indicator of pluripotency dur-
ing initial factorial experiments and prior to a more comprehensive
analysis of gene expression. As mentioned above, the passaging of
ESCs by trypsinization and centrifugation proved to be a key bio-
process step. The importance of trypsin removal was also noted by
Liu et al. [38] who found that residual trypsin could lead to a reduc-
tion in the number of viable cells. Use of default values within the
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Table 1
Statistical reproducibility of manual versus automated culture of mESCs. Data taken from Fig. 4.
Process metric Maximum coefﬁcient of variance (%)
Measured ICD Fixed split
Manual Automated Manual Automated
Viable cell count (1 passage) 2.4 0.8 5.1 3.5
Viable cell count (8 passages) 6.6 2.7 17.8 4.7
E
a
p
<
v
i
t
p
f
i
i
e
r
e
a
m
d
a
i
g
a
a
y
b
w
i
g
d
4
a
b
e
r
t
p
t
a
i
i
g
a
t
p
d
g
o
b
t
ﬂ
a
a
fOct-4-GFP expression (1 passage) 2.9
Oct-4-GFP expression (8 passages) 1.3 
voWareTM software for parameters such as aspiration ﬂow rate
nd position within a well resulted in low cell viabilities (<50%),
oor cell yields (<80%) and the rapid loss of GFP expression (to
80%) after only two sequential passages. As a result of these obser-
ations, various aspects of the trypsinization process were further
nvestigated for optimization purposes including: trypsin incuba-
ion time, aspiration ﬂow rate, dispense ﬂow rate and number of
ipette mixing steps employed.
The measured kinetics of cell detachment from the plate sur-
ace with respect to trypsin incubation time after a single passage
s shown in Fig. 3(a). Trypsinization for a minimum of 4 min  results
n the detachment of over 95% of the cells with no signiﬁcant
ffect on the measured cell viability. The Oct-4-GFP expression
emained high, >90%, provided that the incubation time did not
xceed 10 min, setting a critical upper limit on the process oper-
ting window. With regard to bioprocess reproducibility over
ultiple passages, it is noteworthy that the mean size of the
etached cell aggregates also increased with incubation time (from
pproximately 5 to 40 cells per aggregate). Ideally, for reproducible
noculation of the next plate it would be desirable to obtain a sin-
le cell suspension at this stage. Visual observation indicated that
t short incubation times only small ESC colonies were detached
nd while some discretely suspended cells were obtained, the cell
ield was too low for the process to be viable. With increased incu-
ation times the measured increase in cell yield and aggregate size
as a result of a much greater portion of the cell monolayer becom-
ng detached from the culture surface. For trypsin incubation times
reater than 10 min, especially over multiple ESC passages, a more
ramatic decrease in the ﬁnal viable cell number (∼80%) and Oct-
-GFP expression (∼70%) was measured. In this case the use of
utomation helps ensure the consistent application of 4 min  incu-
ation times which can be difﬁcult for a manual operator to achieve
specially when passaging multiple plates in parallel.
Since the optimum trypsinization time for high cell yield and
etention of Oct-4-GFP expression did not result in dissociation of
he cell aggregates into a single cell suspension, the effect of ‘active
ipetting’ of the aggregates to promote cell dissociation was  inves-
igated. Both the number of aspiration and dispense steps, as well
s their respective ﬂow rates were examined. The data obtained by
ncreasing the number of aspiration steps following a 5 min  trypsin
ncubation time is shown in Fig. 3(b). It was observed that a sin-
le aspiration and dispense step, at volumetric ﬂow rates of 300
nd 600 L s−1, respectively, was sufﬁcient to reduce the size of
he released ESC aggregates to a mean value of just over ten cells
er aggregate. However, the use of at least three aspiration and
ispense steps resulted in the reproducible production of aggre-
ates below ten cells per aggregate. As shown in Fig. 3(b) the use
f these ‘active pipetting’ steps did not signiﬁcantly affect the via-
ility of the cells at the ﬂow rates studied. Further investigation of
he aspiration and dispense ﬂow rates showed that an aspiration
ow rate of 300 L s−1 represented a threshold value, below which
ggregate breakage was minimal, and above which no signiﬁcant
dvantage was  obtained (data not shown). Consequently in the SOP
or the automated passaging of ESCs three aspiration (at 300 L s−1)0.8 2.7 1.7
0.9 2.1 2.0
and dispensing (at 600 L s−1) steps were included after addition
of quenching medium.
3.3. Automated expansion of ESCs
Having identiﬁed the optimum factors and their settings for
each operation in the automated passaging of the ESCs, these were
incorporated within the SOP for cell expansion (Fig. 2(a)). The pro-
tocol involved all major steps routinely used in manual cell culture,
including the centrifugation step which is important for trypsin
removal [38]. In the manual culture process the plate was ‘tapped’
by hand to dislodge cells, a step which was replaced by ‘active pipet-
ting’ in our SOP. Multiple, parallel microwell cultures were then
performed over eight sequential passages.
The automated bioprocess was directly compared to a manual
process. In each case both a ﬁxed split strategy (wherein the cells
are consistently split at a ﬁxed ratio of the total cell number after
2 days culture) or by inoculation of subsequent passages at a mea-
sured ICD (requiring the cell number to be manually counted after
each trypsinization and centrifugation step) was adopted. While it
is possible to integrate automated cell counting within the platform
such an approach is expensive and adds complexity. If reproducible
ESC growth kinetics can be achieved between wells and from pas-
sage to passage then the ﬁxed split strategy offers the beneﬁts
of a simpler bioprocess with reduced risk of equipment failure or
contamination.
The ﬁrst important metric to compare is the accuracy and pre-
cision in determination of the viable cell number at the end of a
single passage. As shown in Table 1, the maximum coefﬁcient of
variance (CV) in the case of both automated bioprocess strategies
is signiﬁcantly less than for the equivalent manual process (based
on four independent measurements of viable cell number from four
separate wells). In the case of cells processed using the ﬁxed split
strategy, the maximum CV was 3.5% for a single automated passage,
while for a single manual passage the maximum CV was 5.1%. In the
case of cells processed by means of the measured ICD strategy the
maximum CV values were lower, as expected given a more pre-
cisely deﬁned inoculum, and the CV for the automated process was
some 3-fold lower than for the manual one. These results conﬁrm
increased uniformity in plate inoculation and cell growth kinetics
using an automated bioprocess. Oct-4-GFP expression levels over
the single passage remain high with low CV values (Table 1) for
both manual and automated processes giving an initial indication
that the ESCs remain pluripotent.
The ESCs were subsequently cultured over eight sequential
passages again measuring the resulting cell number, Oct-4-GFP
expression level and cell viability. Results for the processing of ESCs
using a ﬁxed split strategy for manual and automated bioprocesses
are shown in Fig. 4(a) and (c), respectively. For the manual pro-
cess signiﬁcant variation in the ﬁnal cell number is apparent from
passage to passage. In contrast the measured cell number for the
automated process remains considerably more stable. As shown in
Table 1 over the eight passages, the calculated CV in cell number
determination for the manual process is large at 17.8% while that
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or the automated process is some 3-fold lower at an acceptable
evel of 4.7%. Over the eight passages there was little difference in
he overall viability of the cells with the manual process yielding an
verage cell viability of 88 ± 1.8% and the automated process yield-
ng a value of 88 ± 2.2%. The mean Oct-4-GFP expression levels were
imilarly maintained in both manual (87 ± 1.9%) and automated
rocesses (88 ± 1.8%) resulting in low and acceptable CV values
Table 1). The equivalent and high levels in cell viability and Oct-
-GFP expression after the eighth passage again suggest that the
ells remain pluripotent and respond favourably to both manual
nd automated bioprocesses.
As shown in Fig. 4(b) and (d) the use of a measured and prede-
ned ICD further improved the consistency and reproducibility of
oth manual and automated bioprocesses. For the manual process,
part from the one signiﬁcant deviation in cell number at passage 2,
he calculated CVs over the eight passages were low at 6.6% while
hat for the automated process showed a further 2-fold decrease
Table 1). Again, there was little difference in the measured cell
iabilities (∼88%) and Oct-4-GFP expression levels (∼89%) in either
ase. Irrespective of the operating strategy employed (ﬁxed split
r manual ICD) these results conﬁrm that compared to manual
ultures performed by a well trained and experienced researcher
he application of automation results in the more reliable and pre-
ictable production of cells of consistent viability and pluripotency.
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The spent medium for each passage after 2 days culture was ana-
lyzed for key metabolite levels as shown in Fig. 5. In the majority of
cases the absolute levels of the metabolites were similar suggest-
ing that the application of automation has no measurable effect
on the metabolic activities of the ESCs under investigation. The
metabolite levels are also consistent from passage to passage which
is expected given the similar levels of viability and cell growth
observed (Fig. 4). In future, analysis of metabolic consumption and
production rates would allow us to further evaluate any metabolic
differences between automated and manual processing.
Bioprocess reproducibility will ultimately underpin all aspects
of successful and cost effective manufacture of cells either for drug
discovery or therapy. In this regard, it should also be noted that
automated ESC culture over extended passages has now been per-
formed on multiple occasions in our laboratory over a 6 month
period. Even in the absence of selective antibiotics in the culture
media there has not been one incidence of culture contamina-
tion during contained operation of the robotic platform. There are
a number of advantages to processes carried out in the absence
of antibiotics, which the automation platform facilitates. Primar-
ily, the growth rate and differentiation capacity of ESCs has been
shown to be reduced in the presence of antibiotic agents [39],
thereby signiﬁcantly increasing culture times and adversely affect-
ing space-time yields. In addition, the widespread use of antibiotics
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mmol  L−1), () glucose (g L−1), () lactate (g L−1), (•) ammonium (mmol  L−1). Ce
easured ICD (c) automated, ﬁxed split and (d) automated, measured ICD. Metabol
n stem cell culture has been shown to mask contamination [40],
resenting a potential risk in the use of cell therapies derived
hrough cultures employing antibiotics.
.4. Gene expression analysis during ESC expansion
Quantitative real-time PCR was carried out to establish any dif-
erences in the expression levels of pluripotency markers between
ells passaged manually and those passaged using the robot.
epresentative expression levels (from triplicate experiments) at
assages 1, 5 and 8 were used to determine the effect of the culture
ethod on the pluripotency of the cells. The relative expression
evels of the genes Oct-4, Nanog and Rex-1 were determined for
ach of the bioprocess strategies described in Fig. 4. The sensitiv-
ty of Rex-1 to small changes in the pluripotent state of ESCs has
een previously described [41] and so it was hypothesized that
ny signiﬁcant changes in the pluripotency of the cells caused by
utomated processing would result in changes in the level of Rex-1
xpression. Use of Oct-4 and Nanog are standard in the ESC litera-
ure [29,42,43] and were used to further conﬁrm the pluripotency
f the cells after culture.
Analysis of Rex-1, Oct-4 and Nanog expression, normalized
gainst ˇ-actin expression as a housekeeping gene, is shown in
ig. 6(a)–(c), respectively. There is some variation in the data. For
lutipotency markers Rex-1 and Nanog the level of gene expressionced during the manual and automated cultures shown in Fig. 4: () l-glutamine
saged using the methods described in Fig. 4: (a) manual, ﬁxed split (b) manual,
easured as described in Section 3.3.
is reasonably similar between manual and automated methods as
well as with passage number. In the case of cells processed man-
ually with a ﬁxed split ratio, Rex-1 expression was variable with
that at the end of passage 5 seven times that at passage 1. For cells
processed on the automation platform with a similar split regime,
the Rex-1 levels after 8 passages are very similar at two  times that
observed at passage 1. A similar pattern of Rex-1 expression was
observed in both cases of cells inoculated at a measured ICD. How-
ever, there is large variation in Oct-4 expression during manual
processing as indicated by the error bars. In general, results from
automated cultures showed pluripotency marker expression was
much more consistent compared to manual passages. The mainte-
nance Rex-1, Oct-4 and Nanog in mESCs indicates the amenability of
the cells to automated bioprocessing and the application of consis-
tent and reproducible process operating conditions between wells
and between passages. To further evaluate the quality of cells after
automated processing, assays such as western blot analysis and
PCNA staining would be necessary to determine protein levels and
assess whether there are differences in cell proliferation.
3.5. Embryoid body differentiation of ESCs produced by
automation
In order to conﬁrm that the cells produced on the automation
platform remained pluripotent, the cells harvested after passage
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mig. 6. Quantitative real-time PCR analysis of the cells produced during the manual 
b)  Oct-4, and (c) Nanog,  at passages 1, 5 and 8 using various bioprocess strategie
utomated, measured ICD. Error bars represent 1 standard deviation about the mea
 were subjected to a manual EB differentiation protocol. Results
hown in Fig. 7 indicate that cells processed on the automated
latform maintained their ability to differentiate into cells of the
esoderm, ectoderm and endoderm lineages. Cells produced
y both manual and automated processing stained positive
or brachyury (mesoderm), III-tubulin (ectoderm) and alpha-
etoprotein (endoderm). These results conﬁrm the maintenance of
luripotency during cell expansion as shown in Section 3.4.
.6. Automated directed differentiation of ESCs
The preceding results have illustrated the successful ‘hands-
ree’ expansion of mESCs over multiple passages and the
aintenance of high levels of cell viability and pluripotency gene
xpression. Although expansion of ESCs in an automated fashion is
esirable and required, the most likely ‘end-user’ requirements for
SCs will be deﬁned cell populations in various stages of differenti-
tion. This requires not only a robust and reproducible method for
roducing pluripotent ESCs in bulk (as described in Section 3.3) but
lso an equally robust method for the subsequent directed differ-
ntiation of the resultant cells to desired lineages, or speciﬁc cell
ypes. One of the cell types offering most promise in the area of drug
iscovery and regenerative medicine are neuronal cells [4] and so
ere the focus of the differentiation experiments here.
An SOP for automated monolayer neuronal differentiation
as established in a similar manner to that for cell passaging
Fig. 2(a)). Many of the optimized factor settings used in the
ell expansion SOP, such as deﬁnition of the plate tilt angle
nd aspiration location for maximum removal of spent culture
edium from a well, could be directly translated to the SOP fortomated cultures shown in Fig. 4. Graphs show the relative expression of (a) Rex-1,
anual, ﬁxed split; (ii) manual, measured ICD; (iii) automated, ﬁxed split and (iv)
 3). PCR performed as described in Section 2.6.2.
monolayer differentiation (Fig. 2(b)). Further optimization was
needed in certain areas however. For example, it was necessary
to separately determine maximum aspiration (150 L s−1) and dis-
pensing (300 L s−1) ﬂow rates for cell suspensions containing cells
with signiﬁcant neurite outgrowth. This being a consequence of
their greater sensitivity to the hydrodynamic and shear forces expe-
rienced during pipetting [44].
Once established, the SOP for the monolayer differentiation
protocol enabled the optimized factor settings and ranges to be
reproducibly applied across parallel microwell monolayer differen-
tiation experiments. Again the automated differentiation protocol
using NDIFF–RHBA media was  compared to the standard manual
differentiation process described in Section 2.2. The differentiated
cells produced were analyzed by immunocytochemistry, and the
results are displayed in Fig. 8. It can be seen from the phase con-
trast images that the cell morphology is as expected with neuronal
rosettes present with divergent axons. The presence of the late
neuronal marker III-tubulin [34,45,46] is conﬁrmed in both the
manually processed cells and the cells processed using the auto-
mated SOP. The absence of any staining in the case of the control
(Fig. 8(a, iii)), indicates that there was no non-speciﬁc binding of the
secondary antibody conﬁrming that the observed activity is due to
the presence of III-tubulin. Cells were also stained and analyzed
using ﬂow cytometry (Fig. 9) with the results conﬁrming those seen
in Fig. 8. Levels of neural markers Nestin and III-tubulin expressed
during manual and automated differentiation were found to be
comparable. As neuronal cells can be sensitive to processing, auto-
mated bioprocessing may  be advantageous as it allows shear forces
to be controlled more consistently than in manual bioprocessing.
Being able to control the pipetting speed accurately, for example,
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Fig. 7. ICC analysis of embryoid bodies created after 8 passages through (i and ii) manual and (iii and iv) automated bioprocess strategies for (a) brachyury, (b) III-tubulin
and  (c) alpha-fetoprotein. Blue images (i and iii) show DAPI staining and red images (ii and iv) show actual markers. Scale bars 100 m. ICC performed as described in Section
2.6.3.
Fig. 8. ICC analysis of representative mESCs after 10 days of monolayer differentiation. (a) control; secondary antibody staining only (b) manual differentiation, and (c)
automated differentiation. (i) Phase contrast, (ii) DAPI and (iii) III-tubulin staining. Scale bars 100 m.  ICC performed as described in Section 2.6.3.
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ould reduce damage to the cells during processing. In future work
t would therefore be beneﬁcial to use a functional assay on the neu-
onal cells differentiated on the platform and compare the results
o cells differentiated manually.
. Conclusions
This study has described an integrated automation platform
esigned for the ‘hands-free’ culture of ESCs over multiple pas-
ages and their subsequent directed differentiation into neuronal
recursors. Automated processing of the ESCs showed enhanced
eproducibility and predictability compared to manual methods,
hile maintaining the cells’ pluripotency and ability to differen-
iate into the three embryonic germ layers. It also illustrated a
uccessful framework for the establishment and optimization of
OPs for automation platform operation. The results clearly demon-
trate that the automated bioprocess outperforms the manual one
ven when the latter is performed by a highly trained and experi-
nced researcher. The improved reproducibility of the automated
rocess enables simpler bioprocess strategies to be adopted, such as
he use of ﬁxed split ratios between passages, increasing through-
ut and reducing the risk of equipment failure or contamination.
his study thus conﬁrms the beneﬁts of adopting automated bio-
rocess routes to produce cells both for therapy and for use in basic
iscovery research. Current work in our laboratory is investigating
he control of culture conditions, such as oxygen levels, to improve
he yield and purity of differentiated cell types and the expansion
f human ESCs on the robotic platform.
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